decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Drugs / Fraud alerts / Prescription drug marketing schemes
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an OIG alert about prescription drug marketing schemes involving drug companies, physicians, pharmacies, and other suppliers. It explains the general compliance and fraud-risk concerns raised by these marketing practices, why they matter for Medicaid reimbursement and provider judgment, and the kinds of activities the alert describes at a high level. The content is relevant to compliance professionals, billing and coding staff, pharmacies, physicians, and anyone involved in pharmaceutical marketing or reimbursement oversight.
Why This Topic Matters
It helps readers recognize that certain marketing arrangements may create federal fraud-and-abuse exposure and affect decision-making around prescription drug items reimbursed by Medicaid.
What You Will Learn
- How an OIG fraud alert frames prescription drug marketing practices as a compliance issue
- Why certain marketing arrangements can raise federal anti-kickback and Medicaid reimbursement concerns
- Which provider and supplier groups are commonly implicated in these kinds of alerts
- What broad categories of promotional activities were highlighted in the alert
Who Should Read This
- Compliance professionals
- Physicians
- Pharmacists
- Pharmacies
- Medical office staff
- Billing and reimbursement teams
- Healthcare administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com